---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-007291"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T02:20:29.421796+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Celldex reports Q3 2022 net loss of $26.8M; cash $323.5M; barzolvolimab data readouts planned

## Summary
- Net loss per share ($0.57) in Q3 2022 vs ($0.45) in Q3 2021; nine-month net loss ($85.8M) includes $15M litigation settlement.
- Revenue $0.4M in Q3, down from $0.2M in Q3 2021; R&D expenses rose to $21.6M on barzolvolimab trial and manufacturing.
- Cash, cash equivalents and marketable securities $323.5M as of Sept 30, 2022; management says sufficient through 2025.
- Phase 2 barzolvolimab studies in CSU, CIndU ongoing; 12-week data from Phase 1b CSU due Feb 2023; CIndU cohort data expected Dec 2022.
- CDX-585 (ILT4 & PD-(L)1 bispecific) expected to enter clinic in 2023; CDX-527 (PD-L1 & CD27) discontinued due to evolving competitive landscape and internal hurdles.

## SEC filing metadata
- accession: 0001171843-22-007291
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184322007291/0001171843-22-007291-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184322007291/f8k_110922.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-007291
- JSON: https://secwatch.observer/filing/0001171843-22-007291.json
- Plain text: https://secwatch.observer/filing/0001171843-22-007291.txt

## Key facts
- Earnings Releases
  Celldex Therapeutics, Inc. reported financial results for third quarter of 2022.
  - Period: third quarter of 2022
  - Result: reported results
  source text: On November 9, 2022, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/744218/000117184322007291/0001171843-22-007291-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.